rtmark
LearnBonds.com

Gilead Sciences anti-virus drug performs strongly in early tests, stock soars

Gilead Sciences

Gilead Sciences (NYSE: GILD) stock price bounced after the Chicago-based hospital treating severe coronavirus patients using Gilead Sciences’ antiviral medicine remdesivir said 123 out of 125 patients on the drug were discharged from hospital in less than a week. All these patients were treated with daily doses of Gilead’s remdesivir.

“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane, the University of Chicago infectious disease specialist.

Gilead Sciences jumped as high as 7% higher in Friday stock trading, extending the year to date rally to 26%. Day traders are making buy calls as Gilead’s stock price is likely to move significantly higher if further tests also go well.

President Donald Trump has previously applauded remdesivir’s potential to combat viral diseases. Trump said, “remdesivir seems to have a very good result.”

While Food and Drug Administration and other regulatory agencies have not yet approved any drug for the treatment of this virus, the world has been waiting for the full results of Gilead’s clinical trials.

Several other institutions are also testing remdesivir but no other data has been released as yet. “What we can say at this stage is that we look forward to data from ongoing studies becoming available,” Gilead said.

Gilead Sciences anti-virus drug...

Gilead Sciences has started working with regulators to boost production of remdesivir as the current supply amounts to just 1.5 million doses, accounting for 140000 treatment courses.  “As a result, we have reduced the end-to-end manufacturing timeline from approximately one year to around six months,” wrote chairman and chief executive officer Daniel O’Day wrote on the firm’s website.

Our featured stockbrokers offer an opportunity to buy Gilead Sciences to enjoy the potential share price gains ahead of remdesivir approval from FDA. 

Trusted & Regulated Stock & CFD Brokers

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar

Based in Saudi Arabia, Siraj has a strong understanding of and passion for accounting and finance. He has worked for international clients for many years on several projects related to the stock market, equity research and other business, accounting and finance related projects. Siraj is a published financial analyst on the world's leading websites including SeekingAlpha, TheStreet, MSN, and others.